There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 3 | 96 | 2261 |
| 1 | 1 | 2260.4 |
| 1 | 10 | 2260.3 |
| 6 | 63 | 2260.2 |
| 1 | 11 | 2260.1 |
| Ask | Qty | Orders |
|---|---|---|
| 2261.2 | 2 | 9 |
| 2261.3 | 1 | 6 |
| 2261.4 | 1 | 5 |
| 2261.5 | 1 | 11 |
| 2261.6 | 6 | 69 |
Annual Revenue,rose 29.83%, in the last year to ₹17,443.13 Cr. Its sector's average revenue growth for the last fiscal year was 12.14%.Annual Net Profit,rose 30.06% in the last year to ₹1,361.85 Cr. Its sector's average net profit growth for the last fiscal year was 2.15%.Quarterly Revenue,rose 15.8% YoY to ₹3,959.67 Cr. Its sector's average revenue growth YoY for the quarter was 12.58%.
Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India, specialising in the research, development, manufacturing and sale of branded generics, generics, specialty medicines and OTC products across therapeutic areas including dermatology, respiratory, oncology, cardiology, diabetes, gynaecology, gastroenterology and anti‑infectives. The company operates in more than 80 countries, supported by 11 state‑of‑the‑art manufacturing sites and 4 R&D centres worldwide . Its shares are listed on the National Stock Exchange of India and BSE Limited.
Founded in 1977 by Mr. Gracias Saldanha, Glenmark’s journey features milestones such as: entry into dermatology with Candid Cream in 1979; the first manufacturing unit in Nashik in 1983; entry into respiratory care with Ascoril in 1987; the first R&D centre at Sinnar in 1999; establishing its North American subsidiary in 2003; European entry in 2004; and commissioning a US manufacturing facility at Monroe, North Carolina in 2014 . Recent strategic milestones include the creation of Ichnos Glenmark Innovation (IGI), out‑licensing agreements, and the completed divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited.
Glenmark has sharpened its focus through “Glenmark 3.0” on its core therapy areas—Oncology, Dermatology and Respiratory—while continuing to build its pipeline via IGI and global in‑licensing partnerships . As of March 31, 2025, the Group comprised 43 subsidiaries, 37 of which were located outside India.
For Q4 FY26, Glenmark Pharmaceuticals Ltd reported: Revenue (Net Sales): ₹21465.76 Cr - Down -9.04% year-on-year from ₹23599.35 Cr in Q3 FY26. Net Income (PAT): ₹-739.02 Cr - Down -126.20% year-on-year from ₹2820.66 Cr in Q3 FY26.
The intraday high for Glenmark Pharmaceuticals Ltd on the NSE today (07 Jul 2026) was ₹2,293.90. This compares to the 52-week high of ₹2,474.00 recorded on 29 Apr 2026. Today's high was -7.28% below the 52-week high.
As of 07 Jul 2026, the share price of Glenmark Pharmaceuticals Ltd is ₹2,260.00 on the NSE and ₹2,263.25 on the BSE. The stock opened at ₹2,278.00, touched a high of ₹2,293.90 and a low of ₹2,216.10 during today's session.
Over the last 6 months, Glenmark Pharmaceuticals Ltd has given a return of 7.47%. The stock was priced at ₹2,113.10 on 07 Jan 2026 and has Rise to ₹2,260.00 as of 07 Jul 2026, a change of ₹146.90 per share.
Glenmark Pharmaceuticals Ltd has delivered 22.08% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,474.00 on 29 Apr 2026 and a 52-week low of ₹1,792.60 on 09 Jul 2025. It is currently trading at ₹2,260.00 as of 07 Jul 2026.
The all-time high (ATH) for Glenmark Pharmaceuticals Ltd was ₹2,417.90, recorded on 05 May 2026. At the current price of ₹2,260.00, the stock is trading 6.53% below its all-time high. The all-time low recorded was ₹188.10 on 23 Mar 2020.
Glenmark Pharmaceuticals Ltd has delivered a 242.78% absolute return over the past 5 years, equivalent to a CAGR of 27.94% per annum. The stock was priced at ₹659.32 in Jul 2021 and has risen to ₹2,260.00 as of 07 Jul 2026. An investment of ₹1,00,000 in Glenmark Pharmaceuticals Ltd five years ago would be worth ₹3,42,780.00 today.
Yes,Glenmark Pharmaceuticals Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 15.00 per share between FY2022 and FY2026, with the most recent dividend of ₹2.50 per share for May 26. At the current market price of ₹2,260.00, the trailing dividend yield of Glenmark Pharmaceuticals Ltd stands at 5.00%.
Glenmark Pharmaceuticals Ltd has delivered a return of 7.42% over the last 3 months. The stock was trading at ₹2,114.10 on 07 Apr 2026 and is currently at ₹2,260.00 as of 07 Jul 2026, reflecting a Gain of ₹145.90 per share over this period.
The intraday low for Glenmark Pharmaceuticals Ltd on the NSE today was ₹2,216.10. The stock's 52-week low stands at ₹1,792.60, recorded on 09 Jul 2025. Today's low is 23.62% above the 52-week low, indicating the stock is trading well above its yearly lows.
